


HPV DNA Primary screening with cobas[®] HPV test




SCREEN — TRIAGE — DIAGNOSE

Evidence for change

Pap cytology accuracy is related to a woman's age

Comparison of Pap cytology performance vs. screening age

Confirmed \geq CIN3 in women ages 25-50+ years in ATHENA study (n=40,901)¹



Pap missed 56%
of disease in women ages 25-29

Time for advancement is here


- Pap cytology development in the 1940's revolutionized cervical cancer prevention but cancer rates are no longer declining
- Modern technology using HPV DNA testing identifies the cause of >99% of cervical cancer

Preventable — yet worldwide >250,000 women die of cervical cancer annually²

Earlier detection to preserve cervical health

Cervical disease incidence by age group

Confirmed high-grade disease \geq CIN3 in women 25-50+ years (evaluable women n=40,901)¹




More disease in women ages 25-29
than all women 40 years+ combined

- Delayed detection of progressing disease may result in more invasive treatments, including hysterectomy


Women deserve the accurate screening test, regardless of age

cobas[®] HPV test

Sensitivity



72% increase
in disease detection




>2x

Proven in the ATHENA study, in over 47,000 women ages 21-65 years

Extensive evidence to genotype HPV 16 and HPV 18

Cervical disease by genotype; 10-year cumulative incidence rate

Disease ≥CIN3 in women 30+ years with normal Pap cytology at baseline (n=12,976)⁴




Oncogenic genotypes

cobas[®] HPV test
delivers actionable genotyping
with 3-in-1 result:


- ✓ HPV 16
- ✓ HPV 18
- ✓ pooled 12 high-risk HPV

cobas® HPV test is optimised for suitable results

Risk stratification with integrated sample quality protection



Screen for HPV DNA first-line



*Including CINtec® PLUS Cytology (CE-IVD)
 Global cervical cancer medical guidelines support HPV as the primary screen⁸⁻¹¹

cobas® HPV test for results

<p>✓ Protection from False Negatives</p> <p>Internal Cellular Control: β-globin = Negative result is truly negative</p>	<p>✓ cobas® HPV test</p>	
<p>✓ Protection from False Positives</p> <p>No cross-reactivity⁶, unlike other HPV tests. Conclusive HPV16 and HPV18 genotyping</p>	<p>>20 years real-world experience using HPV DNA (limited data for mRNA)⁷</p>	<p>Global professional guidelines support DNA for HPV screening specifically⁸⁻¹¹</p>

References

1. Wright, T. C., et al. Gynecol Oncol. 2015; 136(2): 189-197
2. WHO HPV and cervical cancer fact sheet, www.who.int/mediacentre/factsheets/fs380/en/. June 2016; Retrieved 10April2018
3. Castle, P. E., et al. Lancet Oncol. 2011; 12(9): 880-890
4. Khan, M. J., et al. J Natl Cancer Inst. 2005; 97:1072-1079
5. Data on file
6. cobas® HPV Test Instructions for Use
7. Arbyn, M., et al. Clin Microbiol Infect. 2015; 21: 817-826
8. Huh, W. K., et al. J Low Genit Tract Dis. 2015; 19(2): 91-96
9. Jeronimo, J., et al. ASCO Resource-Stratified Clinical Practice Guideline. J Global Oncol. 2016; 3(5): 635-657
10. WHO Guidelines for Screening and Treatment of Precancerous Lesions for Cervical Cancer Prevention. Geneva, World Health Org. 2013
11. von Karsa, L., et al. Summary of the Supplements on HPV Screening and Vaccination. Papillomavirus Research. 2015; 1:22-31

COBAS and CINTEC are trademarks of Roche. All other product names and trademarks are the property of their respective owners.

MC-TH-00664 AN6401185 Exp. 01-09-2024

โฆษณาโดยตรงต่อผู้ประกอบการวิชาชีพทางการแพทย์และ สาธารณสุขที่ได้รับการยกเว้นโดยไม่ต้องขออนุญาต

อ่านค่าเตือนในหลอดและ
เอกสารกำกับเครื่องมือแพทย์ก่อนใช้

hpv16and18.com

Roche Diagnostics (Thailand) Ltd.
 18-19th Floor Rasa Tower 1 555 Phaholyothin Road, Chatuchak Chatuchak,
 Bangkok 10900 Thailand

cobas®
HPV TEST

CINtec® PLUS
CYTOLOGY

CINtec®
HISTOLOGY